Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

SAR and biological evaluation of 3-azabicyclo[3.1.0]hexane derivatives as μ opioid ligands.

Lunn G, Roberts LR, Content S, Critcher DJ, Douglas S, Fenwick AE, Gethin DM, Goodwin G, Greenway D, Greenwood S, Hall K, Thomas M, Thompson S, Williams D, Wood G, Wylie A.

Bioorg Med Chem Lett. 2012 Mar 15;22(6):2200-3. doi: 10.1016/j.bmcl.2012.01.099. Epub 2012 Feb 2.

PMID:
22357342
2.

Synthesis, opioid receptor binding, and bioassay of naltrindole analogues substituted in the indolic benzene moiety.

Ananthan S, Johnson CA, Carter RL, Clayton SD, Rice KC, Xu H, Davis P, Porreca F, Rothman RB.

J Med Chem. 1998 Jul 16;41(15):2872-81.

PMID:
9667975
3.

Discovery and synthesis of a new class of opioid ligand having a 3-azabicyclo[3.1.0]hexane core. An example of a 'magic methyl' giving a 35-fold improvement in binding.

Lunn G, Banks BJ, Crook R, Feeder N, Pettman A, Sabnis Y.

Bioorg Med Chem Lett. 2011 Aug 1;21(15):4608-11. doi: 10.1016/j.bmcl.2011.05.132. Epub 2011 Jun 16.

PMID:
21737265
4.

Synthesis of 3,6-diazabicyclo[3.1.1]heptanes as novel ligands for the opioid receptors.

Loriga G, Manca I, Murineddu G, Chelucci G, Villa S, Gessi S, Toma L, Cignarella G, Pinna GA.

Bioorg Med Chem. 2006 Feb 1;14(3):676-91. Epub 2005 Oct 20.

PMID:
16243530
5.

Biaryl piperidines as potent and selective delta opioid receptor ligands.

Liras S, McHardy SF, Allen MP, Segelstein BE, Heck SD, Bryce DK, Schmidt AW, Vanase-Frawley M, Callegari E, McLean S.

Bioorg Med Chem Lett. 2010 Jan 15;20(2):503-7. doi: 10.1016/j.bmcl.2009.11.113. Epub 2009 Nov 26.

PMID:
20015649
6.

Novel ligands for the opioid receptors: synthesis and structure-activity relationships among 5'-aryl and 5'-heteroaryl 17-cyclopropylmethyl-4,5 alpha-epoxypyrido[2',3':6,7]morphinans.

Ananthan S, Khare NK, Saini SK, Davis P, Dersch CM, Porreca F, Rothman RB.

Bioorg Med Chem. 2003 Sep 1;11(18):4143-54.

PMID:
12927876
7.

Synthesis and opioid receptor affinity of a series of 2, 4-diaryl-substituted 3,7-diazabicylononanones.

Siener T, Cambareri A, Kuhl U, Englberger W, Haurand M, Kögel B, Holzgrabe U.

J Med Chem. 2000 Oct 5;43(20):3746-51.

PMID:
11020289
8.

Discovery of the first small-molecule opioid pan antagonist with nanomolar affinity at mu, delta, kappa, and nociceptin opioid receptors.

Zaveri NT, Journigan VB, Polgar WE.

ACS Chem Neurosci. 2015 Apr 15;6(4):646-57. doi: 10.1021/cn500367b. Epub 2015 Feb 18.

9.

Probes for narcotic receptor mediated phenomena. 34. Synthesis and structure-activity relationships of a potent mu-agonist delta-antagonist and an exceedingly potent antinociceptive in the enantiomeric C9-substituted 5-(3-hydroxyphenyl)-N-phenylethylmorphan series.

Hiebel AC, Lee YS, Bilsky E, Giuvelis D, Deschamps JR, Parrish DA, Aceto MD, May EL, Harris LS, Coop A, Dersch CM, Partilla JS, Rothman RB, Cheng K, Jacobson AE, Rice KC.

J Med Chem. 2007 Aug 9;50(16):3765-76. Epub 2007 Jul 11.

PMID:
17625813
10.

Kappa-receptor selective binding of opioid ligands with a heterocyclic bicyclo[3.3.1]nonan-9-one structure.

Benyhe S, Márki A, Nachtsheim C, Holzgrabe U, Borsodi A.

Acta Biol Hung. 2003;54(2):147-55.

PMID:
14535620
11.

Novel molecular targets of dezocine and their clinical implications.

Liu R, Huang XP, Yeliseev A, Xi J, Roth BL.

Anesthesiology. 2014 Mar;120(3):714-23. doi: 10.1097/ALN.0000000000000076.

13.

Effect of N-alkyl and N-alkenyl substituents in noroxymorphindole, 17-substituted-6,7-dehydro-4,5alpha-epoxy-3,14-dihydroxy-6,7:2',3'-indolomorphinans, on opioid receptor affinity, selectivity, and efficacy.

McLamore S, Ullrich T, Rothman RB, Xu H, Dersch C, Coop A, Davis P, Porreca F, Jacobson AE, Rice KC.

J Med Chem. 2001 Apr 26;44(9):1471-4.

PMID:
11311071
14.

Highly potent and selective phenylmorphan-based inverse agonists of the opioid delta receptor.

Thomas JB, Zhang L, Navarro HA, Carroll FI.

J Med Chem. 2006 Sep 7;49(18):5597-609.

PMID:
16942033
15.

Opioid binding profiles of new hydrazone, oxime, carbazone and semicarbazone derivatives of 14-alkoxymorphinans.

Monory K, Greiner E, Sartania N, Sallai L, Pouille Y, Schmidhammer H, Hanoune J, Borsodi A.

Life Sci. 1999;64(22):2011-20.

PMID:
10374926
16.

Novel trans-3,4-dimethyl-4-(3-hydroxyphenyl)piperidines as mu opioid receptor antagonists with improved opioid receptor selectivity profiles.

Le Bourdonnec B, Barker WM, Belanger S, Wiant DD, Conway-James NC, Cassel JA, O'Neill TJ, Little PJ, DeHaven RN, DeHaven-Hudkins DL, Dolle RE.

Bioorg Med Chem Lett. 2008 Mar 15;18(6):2006-12. doi: 10.1016/j.bmcl.2008.01.106. Epub 2008 Feb 2.

PMID:
18313920
17.

Identification of the first trans-(3R,4R)- dimethyl-4-(3-hydroxyphenyl)piperidine derivative to possess highly potent and selective opioid kappa receptor antagonist activity.

Thomas JB, Atkinson RN, Rothman RB, Fix SE, Mascarella SW, Vinson NA, Xu H, Dersch CM, Lu Y, Cantrell BE, Zimmerman DM, Carroll FI.

J Med Chem. 2001 Aug 16;44(17):2687-90.

PMID:
11495579
18.

Synthesis and binding affinity of novel mono- and bivalent morphinan ligands for κ, μ, and δ opioid receptors.

Zhang B, Zhang T, Sromek AW, Scrimale T, Bidlack JM, Neumeyer JL.

Bioorg Med Chem. 2011 May 1;19(9):2808-16. doi: 10.1016/j.bmc.2011.03.052. Epub 2011 Mar 26.

19.

Probes for narcotic receptor mediated phenomena. 47. Novel C4a- and N-substituted-1,2,3,4,4a,9a-hexahydrobenzofuro[2,3-c]pyridin-6-ols.

Iyer MR, Rothman RB, Dersch CM, Jacobson AE, Rice KC.

Bioorg Med Chem. 2013 Jun 1;21(11):3298-309. doi: 10.1016/j.bmc.2013.02.060. Epub 2013 Apr 3.

20.

Factors influencing agonist potency and selectivity for the opioid delta receptor are revealed in structure-activity relationship studies of the 4-[(N-substituted-4-piperidinyl)arylamino]-N,N-diethylbenzamides.

Thomas JB, Herault XM, Rothman RB, Atkinson RN, Burgess JP, Mascarella SW, Dersch CM, Xu H, Flippen-Anderson JL, George CF, Carroll FI.

J Med Chem. 2001 Mar 15;44(6):972-87.

PMID:
11300879

Supplemental Content

Support Center